Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Technetium-99 niacinamide polyethylene glycol bicyclic RGD peptide - RDO Pharm

Next Previous
Drug Profile

Technetium-99 niacinamide polyethylene glycol bicyclic RGD peptide - RDO Pharm

Alternative Names: (99m)Tc-3PRGD2; 99mTc 3PRGD2

Latest Information Update: 28 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RDO Pharm
  • Developer Beijing Pharbers Genesis Pharmaceutical Technology; MedAlly Solutions; RDO Pharm; Sun Yat-Sen University
  • Class Amides; Amino acids; Cyclic peptides; Diagnostic agents; Imaging agents; Polyethylene glycols; Radiopharmaceutical diagnostics; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Lung cancer
  • No development reported Cancer; Oesophageal cancer

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in Oesophageal-cancer(Diagnosis, Metastatic disease) in China (Intravitreous, Injection)
  • 28 Jan 2022 No recent reports of development identified for phase-I development in Cancer(Diagnosis, In volunteers) in China (IV, Injection)
  • 01 Aug 2020 Clinical trials in Oesophageal cancer (Diagnosis, Metastatic disease) in China (Intravitreous) (NCT04504565)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top